Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02664961
Recruitment Status : Terminated (Rare tumor type, patients eligible via expanded access.)
First Posted : January 27, 2016
Results First Posted : June 4, 2019
Last Update Posted : July 23, 2019
Sponsor:
Information provided by (Responsible Party):
Tracon Pharmaceuticals Inc.

Brief Summary:
The purpose of the study is to determine the overall response rate of single agent TRC105 and the combination of TRC105 and bevacizumab in patients with refractory GTN (including choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT)). Up to 30 patients will be treated.

Condition or disease Intervention/treatment Phase
Gestational Trophoblastic Neoplasia Choriocarcinoma Placental Site Trophoblastic Tumor Epithelioid Trophoblastic Tumor Drug: TRC105 Drug: Bevacizumab Phase 2

Detailed Description:
TRC105 is a monoclonal antibody that binds to endoglin, an angiogenic target highly expressed on the tumor vessels and tumor cells in gestational trophoblastic neoplasia (GTN). Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) that inhibits angiogenesis and extends survival in patients with a wide variety of solid tumor types. TRC105 has been well tolerated as a single agent and when combined with bevacizumab. These antibodies may be efficacious in refractory GTN, a tumor type that is highly vascular and has been shown to densely express endoglin.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Actual Study Start Date : March 2016
Actual Primary Completion Date : April 2018
Actual Study Completion Date : November 2018


Arm Intervention/treatment
Experimental: TRC105 and/or bevacizumab
All subjects will begin by receiving single agent TRC105 weekly. In the case of a complete response to single agent TRC105, subjects will continue to receive single agent TRC105 for at least 3 months following complete response. In the case of a partial response (without a complete response) to single agent TRC105, bevacizumab every two weeks will be added. In the absence of a partial or complete response to single agent TRC105, subjects will receive single agent bevacizumab every two weeks. In the absence of a complete response to single agent bevacizumab, or for subjects who have documented disease progression on a prior bevacizumab containing regimen, subjects will receive TRC105 weekly and bevacizumab every two weeks.
Drug: TRC105
Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
Other Name: Chimeric Antibody (TRC105) to CD105

Drug: Bevacizumab
Bevacizumab will be dosed every two weeks.
Other Name: Avastin




Primary Outcome Measures :
  1. Overall Response Rate on TRC105 Alone and on the Combination of TRC105 and Bevacizumab [ Time Frame: 8 weeks ]
    Antitumor Activity of Single Agent TRC105 and the Combination of TRC105 and Bevacizumab will be assessed via RECIST 1.1 and by measuring circulating bHCG. Disease progression is defined as >20% increase (the absolute increase must be ≥10 IU/L) above the nadir on consecutive measurements separated by at least two weeks; Partial response is defined as a hCG decrease of 50% or more from starting value on consecutive measurements; Complete response will be defined as normalization of hCG on consecutive measurements separated by at least two weeks; Stable disease will be defined as the absence of response or progression on 3 consecutive measurements separated by at least two weeks.


Secondary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: 8 weeks ]
    Median Progression-Free Survival (PFS) via Serum hCG levels and response evaluation according to RECIST version 1.1 as a preliminary measure of the antitumor activity of TRC105. Disease progression is defined as >20% increase (the absolute increase must be ≥10 IU/L) above the nadir on consecutive measurements separated by at least two weeks; Partial response is defined as a hCG decrease of 50% or more from starting value on consecutive measurements; Complete response will be defined as normalization of hCG on consecutive measurements separated by at least two weeks; Stable disease will be defined as the absence of response or progression on 3 consecutive measurements separated by at least two weeks. Patients must have screening (baseline) and at least one on study CT scan to be considered evaluable.

  2. Overall Response Rate on Bevacizumab Alone [ Time Frame: 8 weeks ]
    Overall Response Rate on bevacizumab alone according to RECIST 1.1 in combination with serum hCG levels. Disease progression is defined as >20% increase (the absolute increase must be ≥10 IU/L) above the nadir on consecutive measurements separated by at least two weeks; Partial response is defined as a hCG decrease of 50% or more from starting value on consecutive measurements; Complete response will be defined as normalization of hCG on consecutive measurements separated by at least two weeks; Stable disease will be defined as the absence of response or progression on 3 consecutive measurements separated by at least two weeks.

  3. Maximum Plasma Concentration (Cmax) of TRC105. [ Time Frame: cycle 2 day 1 (28 days after initiation of dosing) ]
    Mean serum TRC105 concentrations were assessed at cycle 1 and cycle 2 on day 1, 8, 15, and 22 and on day 1 of every subsequent cycle using validated methods in order to determine the Cmax of TRC105

  4. TRC105 Immunogenicity as Assessed by Anti-Product Antibody (APA). [ Time Frame: 8 weeks ]
    Anti-Product Antibody (APA) concentrations will be measured using validated ELISA methods at the time points specified in the protocol. APA concentrations will be evaluated in the context of pharmacokinetic parameters and AE profiles. Number of patients with positive APA titers on study will be reported.

  5. Frequency and Severity of Adverse Events [ Time Frame: 20 months ]
    Determine frequency and severity of adverse events as assessed by NCI CTCAE (Version 4.03)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Willingness and ability to consent for self to participate in study
  2. Willingness and ability to comply with study procedures
  3. Elevated serum hCG (in cases of choriocarcinoma); elevated hCG or measurable disease (in cases of PSTT or ETT)
  4. Histologically proven trophoblastic neoplasia, or clinically demonstrated trophoblastic neoplasia that has progressed following treatment with at least one chemotherapy regimen that included 2 or more chemotherapy agents.
  5. Age of 16 years or older
  6. ECOG performance status ≤ 1
  7. Resolution of all acute adverse events resulting from prior cancer therapies to NCI CTCAE grade ≤ 1 or baseline
  8. Adequate organ function

Exclusion Criteria:

  1. Male
  2. Prior treatment with TRC105
  3. . Current treatment on another therapeutic clinical trial
  4. Uncontrolled chronic hypertension defined as systolic > 150 or diastolic > 90 despite optimal therapy
  5. Significant pericardial effusion, pleural effusion, or ascites
  6. Active bleeding or pathologic condition that carries a high risk of bleeding
  7. Tumors located in the central chest or other location where bleeding is associated with high morbidity
  8. Thrombolytic use (except to maintain i.v. catheters) within 10 days prior to first day of study therapy
  9. Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) within the past 6 months. Deep venous thrombosis within 6 months, unless the patient is therapeutically anti-coagulated for at least 2 weeks. In this situation, low molecular weight heparin is preferred
  10. Known active viral or nonviral hepatitis
  11. Pregnant or actively breastfeeding without intention to discontinue prior to initiation of study
  12. Open wounds or unhealed fractures within 28 days of starting study treatment
  13. History of peptic ulcer disease or erosive gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment
  14. History of gastrointestinal perforation or fistula in the past 6 months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved
  15. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
  16. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study
  17. History of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for brain edema for at least 28 days
  18. Receipt of systemic anticancer therapy, including investigational agents, within 28 days of starting study treatment. If anticancer therapy was given within 28 days of starting study treatment, patients may be included if 5 times the elimination half-life of the drug has passed
  19. Patients who have received wide field radiotherapy ≤ 28 days (defined as > 50% of volume of pelvic bones or equivalent) or limited field radiation for palliation < 14 days prior to starting study treatment or those patients who have not recovered adequately from side effects of such therapy
  20. Major surgical procedure or significant traumatic injury within 6 weeks prior to study registration or not fully recovered from any such procedure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02664961


Locations
Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Ohio
Ohio State University
Columbus, Ohio, United States, 43210
United States, Texas
UT Southwestern
Dallas, Texas, United States, 75390
Sponsors and Collaborators
Tracon Pharmaceuticals Inc.
Investigators
Layout table for investigator information
Study Director: Charles Theuer, MD, PhD Tracon Pharmaceuticals Inc.
  Study Documents (Full-Text)

Documents provided by Tracon Pharmaceuticals Inc.:
Statistical Analysis Plan  [PDF] August 7, 2018
Study Protocol  [PDF] September 27, 2016


Layout table for additonal information
Responsible Party: Tracon Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT02664961     History of Changes
Other Study ID Numbers: 105GTN201
First Posted: January 27, 2016    Key Record Dates
Results First Posted: June 4, 2019
Last Update Posted: July 23, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Tracon Pharmaceuticals Inc.:
TRC105
CD105
Endoglin
Angiogenesis inhibitor
GTN
Bevacizumab
Avastin
Additional relevant MeSH terms:
Layout table for MeSH terms
Choriocarcinoma
Trophoblastic Neoplasms
Gestational Trophoblastic Disease
Trophoblastic Tumor, Placental Site
Neoplasms
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Pregnancy Complications, Neoplastic
Pregnancy Complications
Bevacizumab
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Immunologic Factors